| Video
Drs. Hah and Prasad review the current evidence on long-term opioid therapy for chronic non-cancer pain, and discuss some approaches to achieving a successful transition to pain management without opioids.
| Video
Opioid induced respiratory depression is associated with over 16,000 deaths in the US each year, and the risks of opioid therapy are not fully understood by many prescribers. Dr. Fudin reviews some of the unanticipated concerns, with a focus on assessing and managing risk for respiratory depression...
| Video
Recent guidelines from the CDC strongly urge a reduction in opioid prescribing in favor of a multidisciplinary approach for the treatment of chronic pain. Dr. Silverman discusses how frontline practitioners can contextualize this information to help patients achieve better functionality and quality...
| Article
Prescriptions for opioids written for patients in the emergency department are for smaller doses and of shorter duration than are prescriptions written elsewhere, say findings from a study led by Mayo Clinic. The same study concludes that these patients are less likely to become long-term opioid...
| Article
A new study conducted by researchers from the University of Virginia School of Medicine’s Department of Public Health services has uncovered a disturbing reason for breast cancer patients’ failure to complete the hormone therapy regimen that is considered essential for long-term survival following...
| Article
The 2016 CDC guidelines on opioid prescribing have been faulted in some quarters for a lack of scientific basis, and an article earlier this week discusses a recent study of the federal review process used in their development. Led by past PAINWeek faculty member Daniel Carr, MD, MA, professor of...
| Video
Concern over opioid abuse is amplifying interest in opioid induced hyperalgesia among governing bodies and payor organizations. Dr. Harden discusses the current state of the science surrounding OIH, including terminology, technology/methodology, and existing evidence. Additionally, he offers some...
| Article
While seeking to uncover evidence of racial disparities in the treatment of migraine, researchers at University of Michigan Medical School documented an entirely different problem: overuse of opioids as migraine therapy across all racial groups. Based on the knowledge that African-Americans are at...
| Article
I think that buprenorphine actually should be one of the first line opioids. Pharmacologically, it's really a different animal. It's in the same kingdom, but just a different animal. Buprenorphine is available in two products that are specifically FDA approved for pain. Belbuca, which is the buccal...
| Article
Buprenorphine was approved for the treatment of opioid use disorder in 2002, with the stipulation that prescribing clinicians obtain a waiver from the Substance Use and Mental Health Services Administration (SAMHSA), and with limitations on how many patients those authorized prescribers may treat in...